Your browser doesn't support javascript.
loading
Integrative Transcriptomic and Single-Cell Protein Characterization of Colorectal Carcinoma Delineates Distinct Tumor Immune Microenvironments Associated with Overall Survival.
Hissong, Erika; Bhinder, Bhavneet; Kim, Junbum; Ohara, Kentaro; Ravichandran, Hiranmayi; Assaad, Majd Al; Elsoukkary, Sarah; Shusterman, Michael; Khan, Uqba; Eng, Kenneth Wha; Bareja, Rohan; Manohar, Jyothi; Sigouros, Michael; Rendeiro, Andre F; Jessurun, Jose; Ocean, Allyson J; Sboner, Andrea; Elemento, Olivier; Mosquera, Juan Miguel; Shah, Manish A.
Affiliation
  • Hissong E; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, 525 E 68th St, New York, NY 10065; Englander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian, 413 E 69th St, New York, NY 10021, USA.
  • Bhinder B; Englander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian, 413 E 69th St, New York, NY 10021, USA.
  • Kim J; Englander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian, 413 E 69th St, New York, NY 10021, USA.
  • Ohara K; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, 525 E 68th St, New York, NY 10065; Englander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian, 413 E 69th St, New York, NY 10021, USA.
  • Ravichandran H; Englander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian, 413 E 69th St, New York, NY 10021, USA.
  • Assaad MA; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, 525 E 68th St, New York, NY 10065; Englander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian, 413 E 69th St, New York, NY 10021, USA.
  • Elsoukkary S; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, 525 E 68th St, New York, NY 10065, USA.
  • Shusterman M; Department of Medicine, Hematology and Medical Oncology, Weill Cornell Medicine, 525 E 68th St New York, NY, USA.
  • Khan U; Department of Medicine, Hematology and Medical Oncology, Weill Cornell Medicine, 525 E 68th St New York, NY, USA.
  • Eng KW; Englander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian, 413 E 69th St, New York, NY 10021, USA.
  • Bareja R; Englander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian, 413 E 69th St, New York, NY 10021, USA.
  • Manohar J; Englander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian, 413 E 69th St, New York, NY 10021, USA.
  • Sigouros M; Englander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian, 413 E 69th St, New York, NY 10021, USA.
  • Rendeiro AF; Englander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian, 413 E 69th St, New York, NY 10021, USA; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 14, AKH BT 25.3, 1090 Wien, Austria.
  • Jessurun J; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, 525 E 68th St, New York, NY 10065, USA.
  • Ocean AJ; Englander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian, 413 E 69th St, New York, NY 10021, USA; Department of Medicine, Hematology and Medical Oncology, Weill Cornell Medicine, 525 E 68th St New York, NY, USA.
  • Sboner A; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, 525 E 68th St, New York, NY 10065; Englander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian, 413 E 69th St, New York, NY 10021, USA; Institute for Computational Biomedicine, Weill Cornell Med
  • Elemento O; Englander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian, 413 E 69th St, New York, NY 10021, USA; Department of Physiology and Biophysics, Weill Cornell Medicine, 525 E 68th St. New York, NY, USA; Institute for Computational Biomedicine, Weill Cornell Medicine, 52
  • Mosquera JM; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, 525 E 68th St, New York, NY 10065; Englander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian, 413 E 69th St, New York, NY 10021, USA.
  • Shah MA; Englander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian, 413 E 69th St, New York, NY 10021, USA; Department of Medicine, Hematology and Medical Oncology, Weill Cornell Medicine, 525 E 68th St New York, NY, USA.
Res Sq ; 2024 Jul 25.
Article in En | MEDLINE | ID: mdl-39108491
ABSTRACT
Colorectal carcinoma (CRC) is a heterogeneous group of tumors with varying therapeutic response and prognosis, and evidence suggests the tumor immune microenvironment (TIME) plays a pivotal role. Using advanced molecular and spatial biology technologies, we aimed to evaluate the TIME in patients with CRC to determine whether specific alterations in the immune composition correlated with prognosis. We identified primary and metastatic tumor samples from 31 consented patients, which were profiled with whole-exome sequencing and bulk RNA-seq. Immune cell deconvolution followed by gene set enrichment analysis and unsupervised clustering was performed. A subset of tumors underwent in situ analysis of the TIME spatial composition at single-cell resolution through Imaging Mass Mass Cytometry. Gene set enrichment analysis revealed two distinct groups of advanced CRC, one with an immune activated phenotype and the other with a suppressed immune microenvironment. The activated TIME phenotype contained increased Th1 cells, activated dendritic cells, tertiary lymphoid structures, and higher counts of CD8+ T cells whereas the inactive or suppressed TIME contained increased macrophages and a higher M2/M1 ratio. Our findings were further supported by RNA-seq data analysis from the TCGA CRC database, in which unsupervised clustering also identified two separate groups. The immunosuppressed CRC TIME had a lower overall survival probability (HR 1.66, p=0.007). This study supports the pertinent role of the CRC immune microenvironment in tumor progression and patient prognosis. We characterized the immune cell composition to better understand the complexity and vital role that immune activity states of the TIME play in determining patient outcome.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Res Sq Year: 2024 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Res Sq Year: 2024 Document type: Article Affiliation country: United States